Clinical Trial Update: Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines

View source ↗

Summary

A completed NCI clinical trial aimed at predicting and testing HIV antigenic sites recognized by T lymphocytes for the development of synthetic vaccines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HIV Infections, Healthy | Status: COMPLETED